Osteopetrotic (o'/op) mutant mice suffer from congenital osteopetrosis due to a severe deficiency of osteoclasts. Furthermore, the total number of mononuclear phagocytes is extremely low in affected mice. Serum, 11 tissues, and different cell and organ conditioned media from op/op mice were shown to be devoid of biologically active colonystimulating factor 1 (CSF-1), whereas all of these preparations from littermate control +/+ and +/op mice contained the
growth factor. The deficiency was specific for CSF-1 in that serum or conditioned media from op/op mice possessed elevated levels of at least three other macrophage growth factors. Partial correction of the op/op defect was observed following intraperitoneal implantation of diffusion chambers containing L929 cells, which in culture produce CSF-1 as their sole macrophage growth factor. No rearrangement of the CSF-1 gene in op/op mice was detected by Southern analysis. However, in contrast to control lung fibroblasts, which contained 4.6-and 2.3-kilobase CSF-1 mRNAs, only the 4.6-kilobase species was detected in op/op cells. An alteration in the CSF-1 gene is strongly implicated as the primary defect in op/op mice because they do not contain detectable CSF-1, their defect is correctable by administration of CSF-1, the op locus and the CSF-1 gene map within the same region of mouse chromosome 3 , their CSF-1 mRNA biosynthesis is altered, and the op/op phenotype is consistent with the phenotype expected in a CSF-1 deficient mouse.
Mice homozygous for the op mutation mapping on chromosome 3 suffer from congenital osteopetrosis due to a severe deficiency ofosteoclasts (1, 2) and macrophages (3) . They are smaller and more stubby in appearance than their normal littermates, possessing extensive skeletal deformities and a lower body weight. They also have a lower life-span and very poor breeding performance (2) . The unimpaired ability of macrophage progenitors from osteopetrotic (op/op) mice to generate macrophages in vitro when incubated with macrophage growth factors (3) suggests that the deficiency of macrophages in vivo is caused by the absence or deficiency of a macrophage growth factor and/or an overabundance of macrophage growth inhibitor. Significantly, impairment of macrophage colony-stimulating factor 1 (CSF-1) production by cultured calvaria of op/op mice has been recently reported (4) . If the defect in the op/op mouse could eventually be pinpointed to a systemic deficiency of a specific macrophage growth factor or to elevated levels of a growth factor inhibitor, the op/op mouse could serve as an excellent model in which to pursue the biology of growth factor or growth factor inhibitor expression.
In this paper, we report that op/op mice have a systemic and specific deficiency of CSF-1. No inhibitor of macrophage growth could be detected and the deficiency of macrophages, their progenitors, and osteoclasts in op/op mice could be partially corrected by implantation of diffusion chambers containing CSF-1-producing cells. These findings, in conjunction with an observed alteration in CSF-1 mRNA splicing, and other published data (5-7), suggest that the deficiency of CSF-1 may be the primary cause of osteopetrosis and macrophage deficiency in the op/op mouse and support previous evidence (7, 8) indicating that CSF-1 is the macrophage growth factor primarily responsible for normal macrophage and osteoclast maturation in vivo.
MATERIALS AND METHODS
Production of op/op Mice and +/+ and +/op Control Mice. White-bellied agouti (C57BL/6J-Aw-J/Aw-J x C3HeB/ FeJ)F1 females bearing transplanted nonagouti, osteopetrotic (a/a op/op) ovaries and nonagouti males (C57BL/6J x C3HeB/FeJ-a/a)F1 were mated to produce known +/op heterozygotes which were purchased as breeding pairs from The Jackson Laboratory. These heterozygotes were then crossed to produce op/op and normal littermate controls (+/+ or +/op). The op/op mice, which are distinguished from their phenotypically normal +/+ and +/op littermates by an absence of incisors and a characteristic skull deformation (2) , were maintained after weaning on a diet of wet mesh chow.
Preparation of Sera, Conditioned Media (CM), and Tissue Extracts. L929 cell (American Type Culture Collection) CM (LCM) and WEHI-3BD cell (American Type Culture Collection) CM (WCM) were prepared by growing cells to confluence and 1 x 106 cells per ml, respectively, in medium containing 10%o fetal calf serum (GIBCO). Endotoxin (E) serum was collected from the blood of mice injected 4 hr previously with E (Escherichia coli B4:0111, 10 ,ug per mouse) (9) . E lung, E bone, and E skin CM were prepared by culturing for 48 hr lungs, marrow-depleted bones, or skin, respectively, from individual mice that were injected with E 4 hr prior to killing (9) . Pokeweed mitogen spleen CM (PWM SCM) was prepared by culturing splenocytes in the presence of pokeweed mitogen for 7 days (9). Fibroblast CM were obtained from confluent secondary and tertiary cultures of bone or skin fibroblasts. Tissue extracts were prepared as described (10 (12) . As these cells also respond to IL-3, the response was attributed to GM-CSF only when IL-3 was not detected in a parallel assay of the particular sample. IL-3 concentrations were determined using a subline of FDCP-1 cells (13) that responds exclusively to this factor in a mitogenesis assay (14) . Similarly, IL-2/IL-4 levels were determined using HT-2 cells in a mitogenesis assay (14) . Although HT-2 cells respond to IL-2 and IL-4, values are expressed in IL-2 units. G-CSF concentrations were determined using a differentiation induction assay (15, 16) ingly, the frequency of op/op cells responding to PWM SCM was twice that of control mice. However, since the bone marrow cellularity ofthe op/op mice is 10% of normal (3), the total number of progenitor cells responding to the growth factors is reduced, as reported earlier (3). In the case of the spleen, however, in which total cellularity is only slightly reduced in the op/op mice (3), there was an increase in the frequency and total number of macrophage progenitor cells responding to all three growth factor preparations, again more marked in the case of PWM SCM. Thus in agreement with the earlier observations, op/op mice have a reduced number of macrophage progenitors in bone marrow that parallels the decrease in its cellularity, whereas the number of these cells is differentially increased in the spleen.
To investigate whether the failure of macrophage progenitors to proliferate and differentiate in op/op mice is due to a macrophage growth factor deficiency or to the production of a macrophage growth factor inhibitor, we tested the ability of sera and media conditioned by cells prepared from op/op mice to stimulate macrophage colony formation (Table 2) . Unlike E serum from control mice, op/op E serum did not contain detectable macrophage colony-(or cluster, data not shown) stimulating activity. This effect was not due to the presence of colony inhibitory activity in op/op serum, as this serum does not prevent, but rather enhances, colony formation stimulated by either LCM or WCM (plating efficiencies for control E serum alone, 0.401 + 0.049; for LCM alone, 0.334 ± 0.038; for LCM plus op/op E serum, 0.623 ± 0.054; for LCM plus control E serum, 0.587 ± 0.037; for WCM alone, 0.313 ± 0.054; for WCM plus op/op E serum, 0.459 ± 0.043; for WCM plus control E serum, 0.427 ± 0.027). Media conditioned by fibroblasts from bone, skin (Table 2) , and peritoneum (data not shown) of op/op mice were similarly devoid of macrophage colony-stimulating activity, whereas the corresponding CM from control mice possessed high activity. However, E lung CM, PWM SCM (Table 2) , and lung CM (data not shown) from op/op mice contained as high or higher macrophage colony-stimulating activity than the corresponding CM from normal mice, indicating that not all sources of macrophage growth factor from op/op mice were biologically inactive.
Measurement of GM-CSF, IL-3, G-CSF, and IL-2/IL-4 in Preparations from op/op and Control Mice. To determine which growth factors might be produced in lower amounts in op/op mice, the preparations listed in Table 2 were tested for the presence of specific growth factors by using cell lines known to exhibit different growth factor requirements ( Table  3) . The growth factors assayed in this fashion, with the exception of G-CSF, which is produced by cultured macrophages, have direct effects on macrophage proliferation in vitro. Depending on the preparation tested, the op/op mice exhibited either increased or slightly impaired production of GM-CSF and G-CSF. Interestingly, PWM SCM-stimulated lymphoid cells from op/op mice exhibited an increased capacity to produce IL-3 and IL-2/IL-4 compared with lymphoid cells from control mice. Thus the macrophage deficiency in op/op mice could not be ascribed to any ofthese growth factors.
Absence of Biologically Active CSF-1 in Sera, Tissues, and CM Prepared from op/op Mice. The absence of detectable macrophage colony-stimulating activity in op/op E serum and fibroblast CM (Table 2) , which in normal mice contain high concentrations of CSF-1, suggested that a lack of this macrophage-specific growth factor might be associated with the op/op phenotype. Sera, tissue extracts, and CM derived from op/op and control mice were therefore assayed for CSF-1 using a specific radioimmunoassay that only detects biologically active CSF-1 and that is slightly more sensitive than the biological assay for CSF-1 (17) . As shown in Table  4 , neither serum, E serum, nor any of the 11 tissues of op/op mice contained any CSF-1 by this assay, in contrast to control mice. Furthermore, even when op/op derived CM were concentrated up to 18-fold by ultrafiltration, it was not possible to detect any CSF-1 by radioimmunoassay (Table 5 ). These data demonstrate the existence of an absolute CSF-1 deficiency in the sera and tissues of the op/op mouse.
Analysis of op/op DNA and RNA. To determine whether the mutation in the op/op mouse was associated with a major alteration in the CSF-1 gene, Southern analysis of DNA from op/op and control mice was carried out using a mouse CSF-1 cDNA probe. As shown in Fig. 1 a- Partial Correction of the op/op Defect by Implantation of Diffusion Chambers Containing CSF-1-Producing Cells. Correction of the mutant phenotype by CSF-1 administration would provide some evidence that the primary defect in the op/op mouse is due to a CSF-1 deficiency. However, circulating CSF-1 has a half-life of only 10 min (24). Thus, a method for the continual administration of CSF-1 over the prolonged period necessary to demonstrate correction was required. Since CSF-1 is the only macrophage growth factor produced by cultured mouse L929 cells (25), 6-month-old op/op mice were implanted with diffusion chambers containing either CSF-1-producing L929 cells or control medium without cells. After 1 month, the mice were killed for determination of cell or macrophage numbers in the bone marrow, spleen, and periphery. Mice that received L929 cells contained on average 650 units of CSF-1 per ml of plasma compared with 0 units/ml in mice that received diffusion chambers containing medium alone. Thus 1 month after their implantation, the L929 cells were still producing CSF-1 and the circulating concentration was almost half that of a normal mouse (1453 units/ml, Table 4 ). In addition, as shown in Table 6 , op/op mice that received L929 cells exhibited a significantly elevated cellularity in the bone marrow and peritoneal cavity, including an 80-fold increase in the number of peritoneal macrophages, in comparison to op/op mice that received diffusion chambers containing medium alone. The cellular composition of peritoneal lavage from control mice was 80%o lymphocytes, 15% granulocytes, and 5% macrophages, compared with the peritoneal lavage from mice receiving L929 cells, which contained 19% lymphocytes, 15% granulocytes, 66% macrophages, and 1% erythroblasts. Interestingly, 10% of the macrophages from the peritoneal cavities of op/op mice receiving L929 cells were positive for the osteoclast-specific marker (26) tartrate-resistant acid phosphatase, whereas peritoneal lavages from control op/op mice or normal mice were devoid of these cells. Similarly, there were 10.5 ± 3.7 acid phosphatase-positive cells per 1 x 104 cells in the bone marrow of these mice, whereas the bone marrows from control op/op and normal mice were devoid of these cells. These results are consistent with the suggestion that the primary defect in the op/op mouse is the failure to produce biologically active CSF-1.
DISCUSSION
We have shown that the tissues, sera, and CM, which from normal littermate control mice contain biologically active CSF-1, specifically lack this macrophage growth factor if obtained from op/op mice. Our results suggest that the CSF-1 deficiency in op/op mice is absolute. Several findings suggest that this particular growth factor deficiency may be the primary defect in op/op mice. An important result is the observation reported here that the op/op phenotype can be partially corrected by administration of CSF-1. Although the diffusion chamber implantation experiments provide indirect evidence and the correction of the defect was partial, this was to be expected from administration of the growth factor to older op/op mice (see below). It is significant that the op mutation and the CSF-1 gene both map within the same region on chromosome 3-i.e., between Amy and Hao-2 (5, 6). Our Southern analyses of the CSF-1 gene in op/op mice and the normal size and level of expression of the 4.6-kb CSF-1 mRNA in lung fibroblasts from op/op mice suggest that there is no major rearrangement of the CSF-1 gene. However, the presence of this transcript in the absence of detectable CSF-1 protein implies that the defect prevents the production of an active translation product. Interestingly, the failure to detect the 2.3-kb CSF-1 mRNA in op/op lung fibroblasts indicates that there is also a pretranslational alteration in CSF-1 gene expression. Any delineation of the molecular basis of the defect(s) in the op/op mouse must therefore account for both of these observations. Clearly the results presented here strongly implicate the existence of alterations within the CSF-1 gene in op/op mice. Studies are necessary to determine the molecular basis of the op defect(s). Finally, the op/op phenotype itself is consistent with a specific CSF-1 deficiency, as CSF-1 has been implicated in the generation of osteoclasts (7) and it is the only mononuclear phagocyte-specific growth factor described to date.
Despite the correction of bone marrow and peritoneal cellularity in op/op mice, incisors failed to appear and there was no correction of pleural cavity cellularity in those mice given diffusion chambers containing L929 cells. These results imply that local or developmentally regulated expression of CSF-1 is important in the development of certain responsive cell populations. Despite the anticipated technical problems, injection of purified CSF-1 into younger, neonatal mice could therefore result in a more complete correction of the op/op defect. Furthermore, this approach may enable situations to be delineated in which local rather than humoral expression of CSF-1 is required for normal development. Obviously, such studies might also be complemented and developed by appropriate transgenic experiments.
In normal mice, sinusoidally located Kupffer cells and splenic macrophages remove 90% of the circulating CSF-1 by CSF-1 receptor-mediated internalization and intracellular destruction (24) . Thus macrophages, whose production is regulated by CSF-1, play an important role in negatively regulating the concentration of CSF-1 in the circulation. The circulating concentration of GM-CSF was elevated in op/op serum and the concentrations of GM-CSF, IL-3, and IL-2/IL-4 in CM were elevated in media conditioned by certain op/op cells and tissues. These elevations may therefore be explained by compensatory increases in the synthesis of these macrophage growth factors or, alternatively, by a decreased rate of their internalization and destruction by target cells due to the decreased number of macrophages in the tissues of op/op mice. Further investigation of these possibilities utilizing the op/op mouse may illuminate the mechanisms by which these macrophage growth factors are regulated in vivo.
CSF-1 has been found to stimulate the formation of osteoclast-like multinucleated cells in long-term bone marrow cultures of baboon cells (7) . However, others have reported that CSF-1 inhibits the growth of osteoclast precursor-like cells (27) and bone resorption by osteoclasts disaggregated from rat bone (28) . Although it is difficult to explain these latter findings on the basis of the data presented here, it is possible that CSF-1 has an additional role of stimulating the production of cytokines (e.g., monokines) that actually inhibit these processes. Clearly studies in the op/op mouse will be useful in resolving these and other questions relating to the roles of cytokines in osteoclast production and bone resorption.
Apart from more clearly understanding the role of CSF-1 in the regulation of bone resorption, the identification of the op/op mouse as a CSF-1-deficient mutant provides a unique opportunity for studies of CSF-1 action. Precise definition of the range of mononuclear phagocyte and progenitor cell deficiencies in various organs of the op/op mouse should allow the CSF-1 requirement of cell populations in different tissues to be determined. As indicated earlier, by carefully timing CSF-1 administration in reconstitution experiments it should be possible to identify processes that are developmentally regulated by CSF-1. The op/op mouse will be particularly useful in studying the role of processes in which regulation by CSF-1 does not appear to involve mononuclear phagocytes or osteoclasts-e.g., placental development (10, 22, 29) .
Note Added in Proof. Sequencing of polymerase chain reaction products using oligonucleotide primers specific for the coding region of the op/op CSF-1 gene revealed the presence of a nonsense mutation at the codon for amino acid no. 277. Although this mutation can explain the absence of biologically active CSF-1 in the op/op mouse, it is not clear whether it is the only mutation in the op/op CSF-1 gene and, if so, whether it is sufficient to cause the absence of the 2.3-kb CSF-1 mRNA species.
